Centessa Pharmaceuticals (CNTA)

AI Score

Unlock

12.29

0.46 (3.89%)

At close: Apr 17, 2025, 3:59 PM

12.51

1.77%

After-hours: Apr 17, 2025, 06:30 PM EDT

Centessa Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020	Q1 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue	n/a	n/a	n/a	n/a	6.91M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	236.26K	239.86K	248.14K	236.62K	237.76K	89.81K	36.27K	34.7K	31.72K	27.84K	12.01K	12.94K	n/a	2.01K	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	-236.26K	-239.86K	6.66M	-236.62K	-237.76K	-89.81K	-36.27K	-34.7K	-31.72K	-27.84K	-12.01K	-12.94K	n/a	-2.01K	n/a	n/a	n/a	n/a
Operating Income	-74.58M	-46.41M	-43.98M	-36.07M	-35.48M	-40.21M	-47.02M	-48.88M	-41.6M	-49.03M	-68.41M	-53.22M	-58.29M	-38.31M	-41.29M	-19.02M	-3M	-2.12M	-2.13M	-3.19M
Interest Income	4.84M	3.34M	3.24M	2.59M	2.93M	2.95M	2.06M	2.53M	2.16K	77K	25K	104K	n/a	65K	27K	38K	102K	100K	89K	86K
Pretax Income	-110.28M	-41.96M	-43.11M	-37.54M	-36M	-41.47M	-48.94M	-50.04M	-43.84M	-54.02M	-64.68M	-54.42M	-60.66M	-40.16M	-41.45M	-240.29M	-3.29M	-2.14M	-2.23M	-3.01M
Net Income	-111.33M	-42.57M	-43.82M	-38.02M	-37.16M	-38.65M	-24.89M	-50.71M	-43.17M	-53.88M	-64.66M	-54.5M	-60.77M	-40.16M	-41.45M	-240.29M	-3.29M	-2.14M	-2.23M	-3.01M
Selling & General & Admin	13.71M	12.5M	11.16M	13.19M	12.17M	12.02M	13.35M	16.05M	13.77M	12.28M	14.76M	14.38M	12.99M	12.46M	11.84M	8.24M	308K	193K	258K	383K
Research & Development	60.87M	33.9M	32.81M	22.64M	29.97M	28.19M	33.67M	32.83M	27.84M	36.74M	53.65M	36.85M	41.53M	25.85M	18.13M	10.78M	994K	2.57M	1.87M	3.33M
Other Expenses	n/a	n/a	n/a	-1.54M	-878K	-1.68M	-1.53M	-1.35M	-70K	-3.14M	5.36M	196K	235K	-1.91M	-191K	n/a	n/a	n/a	n/a	n/a
Operating Expenses	74.58M	46.41M	43.98M	35.83M	42.15M	40.21M	47.02M	48.88M	41.6M	49.03M	68.41M	51.24M	54.52M	38.31M	29.98M	19.02M	3.18M	2.04M	2.14M	2.92M
Interest Expense	2.48M	2.56M	2.52M	2.53M	2.57M	2.54M	2.45M	2.35M	2.16M	1.84M	1.63M	1.4M	1.27M	65K	27K	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	-247.54K	-141.01K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.52M	n/a	n/a	n/a	n/a
Cost & Expenses	74.58M	46.41M	43.98M	36.07M	42.4M	40.21M	47.02M	48.88M	41.6M	49.03M	68.41M	51.24M	54.52M	38.31M	29.98M	19.02M	3.18M	2.04M	2.14M	2.92M
Income Tax Expense	1.05M	608K	705K	480.73K	1.15M	-2.83M	-24.05M	677K	-664K	-141K	-22K	80K	114K	-65K	-11.34M	3.07	n/a	-22K	-99K	181K
Shares Outstanding (Basic)	132.05M	116.25M	109.49M	99.89M	97.92M	96.65M	95.16M	94.94M	94.6M	94.33M	94.11M	90.51M	89.94M	89.9M	63.52M	87.42M	15M	142.06M	n/a	n/a
Shares Outstanding (Diluted)	132.05M	116.25M	109.49M	99.89M	97.92M	96.65M	95.16M	94.94M	94.6M	94.33M	94.11M	90.51M	89.94M	89.9M	63.52M	87.42M	15M	142.06M	n/a	n/a
EPS (Basic)	-0.84	-0.37	-0.4	-0.38	-0.38	-0.4	-0.26	-0.53	-0.46	-0.57	-0.69	-0.6	-0.68	-0.45	-0.65	-2.75	-0.22	-0.01	n/a	n/a
EPS (Diluted)	-0.84	-0.37	-0.4	-0.38	-0.38	-0.4	-0.26	-0.53	-0.46	-0.57	-0.69	-0.6	-0.68	-0.45	-0.65	-2.75	-0.22	-0.01	n/a	n/a
EBITDA	-107.57M	-39.16M	-40.4M	-34.78M	-33.16M	-38.47M	-46.4M	-48.03M	-41.95M	-51.69M	-62.47M	-52.69M	-58.21M	-39.96M	-41.29M	-240.24M	-3M	-22K	-99K	181K
EBIT	-107.8M	-39.4M	-40.63M	-35.04M	-33.12M	-38.71M	-46.64M	-48.12M	-41.67M	-51.73M	-62.51M	-52.92M	-58.19M	-39.97M	-41.45M	-16.52M	-3M	-2.12M	-2.13M	-3.19M
Depreciation & Amortization	230K	236K	236K	239.86K	248.14K	236.62K	237.76K	89.81K	36.27K	34.7K	31.72K	27.84K	12.01K	12.94K	7K	2.01K	1.5K	2.12M	2.13M	3.19M